About the Company
XOMA Corporation doesn’t want to toil in anonymity. Instead, the company pairs with larger drug firms to develop and market its products, primarily monoclonal antibodies (biotech drugs based on cloned proteins). It’s developing lead candidate gevokizumab with French drugmaker Servier. The firm partners on therapeutics for infectious disease, inflammatory ailments, and autoimmune conditions and receives royalties on drugs developed from licensing its technologies. XOMA has collaborative agreements with pharma companies Takeda Pharmaceutical and Novartis; it also has metabolic and oncology candidates.